PYC Therapeutics (ASX:PYC) received all regulatory approvals to start human trials of its drug candidate for polycystic kidney disease, the company said in a Monday Australian bourse filing.
Polycystic kidney disease is a life-changing disease where multiple cysts form throughout a patient's kidney that increase in size over time.
Dosing of patients in the single ascending dose study is expected to be completed in about 12 months with a budgeted cost of AU$10 million, per the filing. The primary endpoint is treatment-emergent adverse events and treatment-emergent serious adverse events.
The initial human safety and efficacy data are anticipated within the year, the filing added.
Company shares were up nearly 3% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。